BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Continues to Strengthen Position in Plant-Based Health Industry

Healthy Extracts (OTCQB: HYEX) is committed to growth and has aligned its operations to focus on the plant-based health industry. Reflecting this focus, HYEX changed its name from Grey Cloak Tech to align with the company’s objectives and a “Live Life Young Again” strategy. “The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (‘UBN’),” reads a recent article. The company also achieved significant accomplishments in 2020, including a 71% increase in recorded gross revenue, despite the COVID pandemic, as well as elimination of all convertible debt. Further, net shareholder equity increased by $3.7 million. With regards to plant-based products, HYEX introduced “Clinical Immune, a clinically proven immunity product focusing on heart and respiratory health, while sales of the Fuel4Thought Brain Booster product are expected to begin in Q2 after completion of key clinical studies.”

To view the full article, visit https://ibn.fm/D8z7m

About Healthy Extracts Inc.

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending. For more information, visit: www.HealthyExtractsInc.com, www.BergametNA.com or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease 

Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the…

34 minutes ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons…

43 minutes ago

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet…

2 hours ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent…

22 hours ago

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the…

23 hours ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet…

1 day ago